A once-promising study on the drug hydroxychloroquine has been halted by the Henry Ford Health System due to a lack of participants. The study, which began in April, was discontinued before Christmas because only 624 people enrolled for the clinical trial that required 3,000 participants.
Researchers wanted to investigate whether the hydroxychloroquine could prevent or slow the progress of COVID-19, but were forced to terminate, stating “given low recruitment potential, it is unlikely that a positive result will occur.”
According to the Washington Examiner, a previous study by the Henry Ford Health System found that COVID-19 patients who took the drug had half the mortality rate of those who did not. Doctors at Henry Ford Health System in Southeast Michigan said that 26% of patients who did not receive the antimalarial drug died compared to 13% of patients who received hydroxychloroquine during their stay in the hospital.
Read more at NEWSMAX.